Alkermes reports positive Phase 1b ADHD proof-of-concept results
Alkermes announced a Phase 1b study of ALKS 7290 demonstrated clinically meaningful, dose-dependent improvements in ADHD symptoms in adult patients, highlighting potential for differentiated therapies in a high-need area.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed